Conference abstractPublished 8 Sep 2014
Regulatory transparency: Technical, legal and ethical aspects of access to regulatory applications (medicines dossier) - Brazilian approach
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Brazil is 5th biggest pharmaceutical market in the world, and the Brazilian Heath Surveillance Agency (ANVISA) is responsible to evaluate the products quality and safety. The process of expanding access to data on the regulatory framework was highlighted by publication of Federal Law 12.527/2011. Hence, in the field of health regulation, the wide access to data of drugs and related technical documents, especially clinical trials data, is in the expansion at FDA, EMA and ANVISA. A fact to be evaluated is how disclosure policies are built, emphasizing the regulatory impact analysis and detecting the risks and benefits involved. Therefore, is essential the analysis of the legal, technical and ethical aspects involved in the publicity of data, such as: patent rights, confidentiality of commercial information, privacy of research subjects, rules of engagement for accessing, clinical trials registers, electronic application, as well as defining the limits of access and disclosure. The openness will enable public scrutiny and secondary analysis probably resulting in improvement of the products quality and public health development as well as the social accountability, but some boundaries should be respect in order to not frustrate investments on bio-pharmaceutical research and development (R&D) along with not to bias the Agency?s decision-making process, hereafter, disclosures policies has substantial impact over regulatory environment. Clinical study report is essentially significant as contain vital information regard new products, methods and formulations over and above is the primary source of information about the product efficacy.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Varley Dias Sousa”
